← Leaderboards
Bin Guo
University Of North Dakota
$4,731,844
Attributed
$6,197,405
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,197,405 · 10
By mechanism
R01$3,579,456 · 3
P20$2,232,479 · 5
R21$242,220 · 1
R03$143,250 · 1
Top collaborators
- Sanku Mallik5 shared
- Kausik Sarkar5 shared
- Peixuan Guo2 shared
- Piotr Rychahou2 shared
Others in their field
Top investigators on “Cancer Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$394,493,843
- Gregory H Reaman · National Childhood Cancer Foundation$172,801,935
- Richard A Gibbs · Baylor College Of Medicine$159,160,442
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Mary M Horowitz · Medical College Of Wisconsin$153,900,671
- William George Nelson · Johns Hopkins University$111,434,918
Research focus
Cancer CellResponseCancer TherapyTumorCancer EtiologyResearch PersonnelCessation Of LifeRegimenResistanceMouse ModelToxic EffectCancer DiagnosisBaseMediatingOrganNeoplasm MetastasisUnited States National Institutes Of HealthCellsDiagnosticIrinotecanLeucovorinRegulationCenters Of Research ExcellenceOxaliplatin
Grant awards (25)
Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNA$475,445
R01 · FY2025 · CA
Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNA$497,002
R01 · FY2024 · CA
Animal Core Facility$378,766
P20 · FY2020 · GM · contact PI
Animal Core Facility$365,400
P20 · FY2019 · GM · contact PI
Animal Core Facility$367,189
P20 · FY2018 · GM · contact PI
RNA Therapeutics for Targeted Treatment of Colon Cancer$342,809
R01 · FY2018 · CA · contact PI
Echogenic Polymersomes for Triggered Contents Release$287,625
R01 · FY2018 · GM
Acquisition of a high-performance liquid chromatography system$64,145
R01 · FY2018 · GM
Animal Core Facility$380,400
P20 · FY2017 · GM · contact PI
RNA Therapeutics for Targeted Treatment of Colon Cancer$341,702
R01 · FY2017 · CA · contact PI
Echogenic Polymersomes for Triggered Contents Release$287,625
R01 · FY2017 · GM
Animal Core Facility$407,028
P20 · FY2016 · GM · contact PI
RNA Therapeutics for Targeted Treatment of Colon Cancer$299,883
R01 · FY2016 · CA · contact PI
Echogenic Polymersomes for Triggered Contents Release$287,625
R01 · FY2016 · GM
RNA Therapeutics for Targeted Treatment of Colon Cancer$50,395
R01 · FY2016 · CA · contact PI
RNA Therapeutics for Targeted Treatment of Colon Cancer$346,325
R01 · FY2015 · CA · contact PI
Echogenic Polymersomes for Triggered Contents Release$298,875
R01 · FY2015 · GM
COBRE: NDSU: PROJECT 3: MMP-9 IN APOPTOSIS OF PROSTATE CANCEL CELLS$70,541
P20 · FY2011 · RR · contact PI
COBRE: NDSU: PROJECT 3: MMP-9 IN APOPTOSIS OF PROSTATE CANCEL CELLS$70,882
P20 · FY2010 · RR · contact PI
COBRE: NDSU: PROJECT 3: MMP-9 IN APOPTOSIS OF PROSTATE CANCER CELLS$137,555
P20 · FY2009 · RR · contact PI
Chemoprevention of Familial Adenomatous Polyposis by a Combination of 3,3?-Diind$71,750
R03 · FY2009 · CA · contact PI
Chemoprevention of Familial Adenomatous Polyposis by a Combination of 3,3?-Diind$71,500
R03 · FY2008 · CA · contact PI
Mechanisms of Bax Activation in Apoptosis$119,670
R21 · FY2006 · CA · contact PI
Mechanisms of Bax Activation in Apoptosis$122,550
R21 · FY2005 · CA
BCL-G IN APOPTOSIS AND CHEMORESPONSE OF PROSTATE CANCER$54,718
P20 · FY2004 · RR